In the News

News & Publications

  • Filter by type

September 16, 2021 | Press Release
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

Pulmocide raised $92 million in Series C funds in May 2021 to fund a registration program for opelconazole in patients […]

May 27, 2021 | Press Release
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945

– Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and […]

March 11, 2021 | Press Release
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections

London, UK, 11 March 2021 – Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, […]

October 26, 2020 | Publications & Presentations
Pulmocide Presents at US FDA Workshop on Inhaled Antifungal Drug Development

London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening […]

March 2, 2020 | Publications & Presentations
Pulmocide announces four presentations on PC945 at the 9th Advances Against Aspergillosis and Mucormycosis conference in Lugano, Switzerland, 27 February – 1 March, 2020

London, UK, 2 March 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung […]

Scroll to Top